Exact Therapeutics AS (OSL:EXTX) Cash-to-Debt : 38.11 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Exact Therapeutics AS's cash to debt ratio for the quarter that ended in Dec. 2023 was 38.11.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Exact Therapeutics AS could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Exact Therapeutics AS's Cash-to-Debt or its related term are showing as below:

OSL:EXTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 38.11 Med: 244.75 Max: No Debt
Current: 38.11

During the past 7 years, Exact Therapeutics AS's highest Cash to Debt Ratio was No Debt. The lowest was 38.11. And the median was 244.75.

OSL:EXTX's Cash-to-Debt is ranked better than
69.66% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs OSL:EXTX: 38.11

Exact Therapeutics AS Cash-to-Debt Historical Data

The historical data trend for Exact Therapeutics AS's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Exact Therapeutics AS Cash-to-Debt Chart

Exact Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

244.75

4,195.29

60.23

40.63

38.11

Exact Therapeutics AS Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial						60.23	51.34	40.63	27.15	38.11

Competitive Comparison of Exact Therapeutics AS's Cash-to-Debt

For the Biotechnology subindustry, Exact Therapeutics AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Therapeutics AS's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's Cash-to-Debt falls into.

Exact Therapeutics AS Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Exact Therapeutics AS's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	45.573	/	(0.546	+	0.65)
	=	38.10

Exact Therapeutics AS's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	45.573	/	(0.546	+	0.65)
	=	38.10

Exact Therapeutics AS (OSL:EXTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Exact Therapeutics AS Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ostre Aker vei 19, Oslo, NOR, 0581

Website

https://www.exact-tx.com

Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines